CN102861080B - Application of Houttuynoid C in medicine for treating nasopharynx cancer - Google Patents
Application of Houttuynoid C in medicine for treating nasopharynx cancer Download PDFInfo
- Publication number
- CN102861080B CN102861080B CN201210418673.XA CN201210418673A CN102861080B CN 102861080 B CN102861080 B CN 102861080B CN 201210418673 A CN201210418673 A CN 201210418673A CN 102861080 B CN102861080 B CN 102861080B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicine
- application
- nasopharynx cancer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses application of Houttuynoid C in preparation of a medicine for treating nasopharynx cancer, belonging to the technical field of new application of medicine. The invention discovers that Houttuynoid C has the remarkable inhibitory effects on the growth of human nasopharynx cancer cell strains, including HNE1, HNE2, HONE1 and CNE1 through the evaluation of in vitro MTT antineoplastic activity. Therefore, Houttuynoid C can be used for preparing the anti-nasopharynx cancer medicine and has good development and application prospects. The application of Houttuynoid C in preparation of the medicine for treating nasopharynx cancer provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid C on nasopharynx cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to the application of Houttuynoid C in the anti-medicine for nasopharyngeal of preparation.
Technical background
Cancer is one of disease to human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid C the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), purposes for the Houttuynoid C the present invention relates in preparation treatment medicine for nasopharyngeal belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for nasopharyngeal carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, obviously there is significant progress for the control of nasopharyngeal carcinoma simultaneously.
Summary of the invention
The invention provides compound H outtuynoid C in the application of preparing in antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid C in the anti-medicine for nasopharyngeal of preparation, and the structural formula of Houttuynoid C is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid C also has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 1.16 ± 0.09 μ M, 1.89 ± 0.19 μ M, 1.03 ± 0.11 μ M and 2.45 ± 0.24 μ M.Therefore, Houttuynoid C can, for the preparation of anti-medicine for nasopharyngeal, have good development prospect.
Purposes for the Houttuynoid C the present invention relates in preparation treatment medicine for nasopharyngeal belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for nasopharyngeal carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, obviously there is significant progress for the control of nasopharyngeal carcinoma simultaneously.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid C to human nasopharyngeal carcinoma cell line
1. method: the cell in growth logarithmic (log) phase: human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1(buy from Chinese Academy of Sciences's cell bank) with 1.5 × 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid C of 0.01 μ M and 0.001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.This compound suppresses the IC of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 growth
50value is respectively: 1.16 ± 0.09 μ M, 1.89 ± 0.19 μ M, 1.03 ± 0.11 μ M and 2.45 ± 0.24 μ M.
Shown by above-described embodiment, Houttuynoid C of the present invention has good inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.Prove thus, Houttuynoid C of the present invention has anti-nasopharyngeal carcinoma activity, can be for the preparation of anti-medicine for nasopharyngeal.
Claims (1)
- The application of 1.Houttuynoid C in preparation treatment medicine for nasopharyngeal, described compound H outtuynoid C-structure as formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418673.XA CN102861080B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in medicine for treating nasopharynx cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418673.XA CN102861080B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in medicine for treating nasopharynx cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861080A CN102861080A (en) | 2013-01-09 |
| CN102861080B true CN102861080B (en) | 2014-05-14 |
Family
ID=47440398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418673.XA Expired - Fee Related CN102861080B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in medicine for treating nasopharynx cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861080B (en) |
-
2012
- 2012-10-27 CN CN201210418673.XA patent/CN102861080B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861080A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861073B (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102861065B (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102861071B (en) | Application of Houttuynoid A in medicine for treating gastric cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102861097B (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861064B (en) | Application of Houttuynoid E in preparing medicine for treating laryngocarcinoma | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861069B (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SONG HAIPING Free format text: FORMER OWNER: WU JUNHUA Effective date: 20130902 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Song Haiping Inventor after: Wang Hui Inventor after: Zhang Guang Inventor after: Wu Junhua Inventor before: Wang Hui Inventor before: Zhang Guang Inventor before: Wu Junhua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG HUI ZHANG GUANG WU JUNHUA TO: SONG HAIPING WANG HUI ZHANG GUANG WU JUNHUA Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 266071 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130902 Address after: 266071 Shandong Province, Qingdao city Chenghai Road No. 4 Applicant after: Song Haiping Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Applicant before: Wu Junhua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140514 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |